AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04834895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brochure exercise group
Description: Participants were asked to perform 18 exercises specially prepared for neck pain in the brochure according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
Study NCT04783415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Given IV
Study NCT04783415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Given PO
Study NCT05546099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management of BP medications
Description: Patients will be educated on how to manage their home BP based on a pre-determined protocol. They will then monitor home BP and adjust meds accordingly and under the guidance of the clinical pharmacist.
Study NCT05546099 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring of home BP
Description: Patients will be educated on how to monitor home BP and will be educated to contact their primary care provider/CKD provider if the BP is above the goal.
Study NCT05421273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation using passive recharge burst stimulation
Description: Passive recharge burst is marked by a recharge pattern that passively compensates for charge differences.
Study NCT05421273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation using active recharge burst stimulation
Description: Active recharge burst is characterized by negative pulses that directly compensate for charge differences.
Study NCT06203262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FieldForce™ Ablation System Ventricular Tachycardia
Description: Catheter ablation is a minimally invasive procedure. The physician advances multiple catheters into the heart that are used to diagnose and localize abnormal cardiac tissue involved in the initiation and maintenance of ventricular tachycardia and/or PVCs. Once the abnormal tissue is identified a specialized catheter is advanced to the target and energy is applied to destroy the abnormal tissue. The intervention will be identical to the conventional procedure except that an investigational ablation catheter will be used to deliver energy.
Study NCT06203262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FieldForce™ Ablation System Premature Ventricular Contractions
Description: Catheter ablation is a minimally invasive procedure. The physician advances multiple catheters into the heart that are used to diagnose and localize abnormal cardiac tissue involved in the initiation and maintenance of ventricular tachycardia and/or PVCs. Once the abnormal tissue is identified a specialized catheter is advanced to the target and energy is applied to destroy the abnormal tissue. The intervention will be identical to the conventional procedure except that an investigational ablation catheter will be used to deliver energy.
Study NCT06044948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lenses
Description: Daily disposable, silicone hydrogel spherical contact lenses
Study NCT06519370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA018-ADC
Description: Subjects will receive FDA018-ADC 10 mg/kg of body weight via intravenous(IV) infusion on Day1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
Study NCT06519370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: 1.4mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle
Study NCT06519370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest
Study NCT06519370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 800 to 1200 mg/m\^2 will be administered IV on day 1 and Day 8 of each 21 day cycle
Study NCT06519370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: 25 mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle
Study NCT05586217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INCENTIVE SPIROMETRY
Description: * Sit up and hold the device.~* Then Place the mouthpiece spirometer in mouth and make a good seal over the mouthpiece with lips.~* Breathe out (exhale) normally.~* Breathe in (inhale) slowly. A piece in the incentive spirometer will rise as you breathe in. And try to get this piece to rise as high as you can.~* Usually, there is a marker placed by your doctor that tells you how big of a breath you should take.~A smaller piece in the spirometer looks like a ball or disk.~* Your goal should be to make sure this ball stays in the middle of the chamber while you breathe in.~* If you breathe in too fast, the ball will shoot to the top.~* If you breathe in too slowly, the ball will stay at the bottom. Hold your breath for 3 to 5 seconds. Then slowly exhale.
Study NCT05586217 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active cycle of breathing
Description: Breathe in and out gently through your nose if you can. If you cannot, breathe through your mouth instead. If you breathe out through your mouth, it's best to use breathing control with 'pursed lips breathing'. keep your shoulders relaxed.~Try closing your eyes to help you to focus on your breathing and to relax. Breathing control should continue until the person feels ready to progress to the other stages in the cycle. Try to keep your chest and shoulders relaxed.~At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing out. Breathe out gently and relaxed. Repeat 3 - 5 times. Sit up straight with chin tilted slightly up and mouth open.~Take a slow deep breath to fill lungs about three quarters full. Hold breath for two or three seconds. Exhale forcefully, but slowly, in a continuous exhalation to move mucus from the smaller to the larger airways
Study NCT05586217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing
Description: Breathe in and out gently through your nose if you can. If you cannot, breathe through your mouth instead. If you breathe out through your mouth, it's best to use breathing control with 'pursed lips breathing'. keep your shoulders relaxed.~Try closing your eyes to help you to focus on your breathing and to relax. Breathing control should continue until the person feels ready to progress to the other stages in the cycle. Try to keep your chest and shoulders relaxed.~At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing out. Breathe out gently and relaxed. Repeat 3 - 5 times. Sit up straight with chin tilted slightly up and mouth open.~Take a slow deep breath to fill lungs about three quarters full. Hold breath for two or three seconds. Exhale forcefully, but slowly, in a continuous exhalation to move mucus from the smaller to the larger airways
Study NCT06217731 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Laser+clonazepam
Description: treated with the Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month and Rivotril 0.25mg once every 24 hours for a month
Study NCT06217731 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Laser Sham
Description: INACTIVE Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month
Study NCT06217731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Active Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month
Study NCT04718103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3511294
Description: GSK3511294 was administered using a pre-filled syringe.
Study NCT04718103 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as normal saline using a pre-filled syringe.
Study NCT06217731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: Rivotril 0.25mg once every 24 hours for a month
Study NCT06424327 — intervention group
Intervention type: OTHER
Intervention: Patient-Reported Outcomes Measurement Information System
Description: Participants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0)
Study NCT05450302 — intervention group
Intervention type: OTHER
Intervention: PURE EP (Observational Study)
Description: This is an observational study. No interventions involved in this study.
Study NCT06474962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pause
Description: 7 days of no e-cigarette consumption
Study NCT05823441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Volunteers inhale 24 units of oxytocin spray
Study NCT05823441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Volunteers inhale 24 units of oxytocin spray
Study NCT05823441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers inhale 24 units of placebo spray
Study NCT05823441 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stranger
Description: Volunteers watch a video of a pain test and attach a photo of a stranger
Study NCT05823441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acquaintance
Description: Volunteers watch a video of a pain test and attach a photo of an acquaintance
Study NCT05823441 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acquaintance
Description: Volunteers watch a video of a pain test and attach a photo of an acquaintance
Study NCT04795622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultherapy treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT04795622 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Untreated-control / delayed-treatment
Description: Untreated-control, followed by Ultherapy treatment (focused ultrasound energy delivered below the surface of the skin)
Study NCT05501912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABM-1310
Description: Dose escalation starting dose will be based on a priming dose one level below the highest safe dose or two levels below the MTD that has been tested in US clinical trials.~Dose expansion will be initiated at the MTD or the optimal dose determined by the SMC as a fixed dose level.
Study NCT06511882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine
Description: Standard of Care Intravenous (IV) infusion
Study NCT05423080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus injection of remimazolam
Description: Participants in this group are administered 0.2 mg/kg remimazolam via the bolus injection method for 20 seconds during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will administer additional doses of 0.05 mg/kg repeatedly until LOC occurs.
Study NCT05423080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of remimazolam
Description: Participants in this group are administered remimazolam at a rate of 6 mg/kg/hr via the continuous infusion method during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will escalate infusion dose to 12 mg/kg/hr until LOC occurs.
Study NCT06511882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: Standard of Care Intravenous (IV) infusion
Study NCT06511882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Venetoclax
Description: Standard of Care PO (By Mouth)
Study NCT05996653 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Saturation Transfer (ST)-MRI
Description: Non-contrast magnetic resonance imaging Saturation Transfer scans consisting of magnetization transfer (MT) and chemical exchange saturation transfer (CEST)
Study NCT03497793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNUBY
Description: Following written informed consent, mother will be issued with an appropriate sized SNUBY® for her use only. The infant will be placed in skin-to-skin in SNUBY®, infant chest to mother's chest whilst the mother is seated on a reclining chair, allowing the infant to be further stabilised by gravity. Monitor wires, IV lines and/or ventilation tube will be secured using the ties on the SNUBY®. The infant's temperature, pulse and SaO2 will be recorded prior to skin-to-skin, repeated as required for the infant's clinical condition or at 30min intervals for the duration of skin-to-skin. Maternal and infant behaviour will be recorded, including spontaneous breastfeeding. The time taken to put the infant into skin-to-skin care, time in skin-to-skin care and time to return to cot will be recorded.
Study NCT04802070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CIK
Description: Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory (4 dose levels)
Study NCT05437211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual-reality (VR) Based Solution
Description: VR-based solution comprises a mobile phone application including explanation on the different steps to be followed to perform infusions in satisfactory conditions, notably as regards safety, as well as VAS for pain and anxiety to be completed at each Factor VIII or Factor IX infusion between inclusion and the Week 4 visit. It also comprises a 3D mask (to be used before or during infusions) including simulation of the infusions themselves (before infusion) and a relaxing and distracting content (during and after infusions).
Study NCT06550271 — intervention group
Intervention type: DRUG
Intervention: Rapamycin
Description: Rapamycin in 2 different dosage forms (compounded and generic)
Study NCT02642523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Subjects will receive an intravenous infusion of recombinant human b-type natriuretic peptide (BNP) (Nesiritide) over 2 hours at 2 doses: 0.003 ug/kg/min for 1 hour, followed by 0.01 ug/kg/min for 1 hour. Nesiritide (Johnson and Johnson) is FDA-approved for the treatment of heart failure. Study investigators received approval from the FDA for an IND exemption for nesiritide in this study. While receiving the BNP infusion, subjects will also receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
Study NCT02642523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: The hyperinsulinemic-euglycemic insulin clamp, which will last between 2-2.5 hours, involves continuous intravenous infusions of human regular insulin and of dextrose solution. Simultaneously, subjects receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
Study NCT02642523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects will receive an intravenous infusion of normal (0.9%) saline over 2 hours at a rate of 0.25 ml/kg/min. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
Study NCT03548233 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: bcg vaccine
Description: live attenuated vaccine
Study NCT04883788 — intervention group
Intervention type: OTHER
Intervention: Pandemic period
Description: Perioperative care (nursing and physiotherapy) provided to patients treated with hip and knee replacement during the pandemic period
Study NCT05768789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Buoy Electrolyte
Description: Buoy intervention amount is 4% of total body weight given in 16 divided doses over 4 hours.
Study NCT05768789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nuun
Description: Nuun intervention given as 1L bolus and then free water in divided doses for a total of 4% total body weight.
Study NCT05768789 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water serves as a control
Study NCT05696704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: Mindfulness Based Cognitive Therapy
Description: Individual tele-therapy 12 to 16 weeks
Study NCT05696704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: Behavior Activation
Description: Individual therapy 12 to 16 weeks
Study NCT04845698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-Dashboard
Description: i-Dashboard is a team-designed, patient-centered electronic medical record viewer, which retrieves data from multiple databases and provides a quick representation of essential metrics for each patient.
Study NCT05715307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive training for endocrinologists in T2DM management
Description: One-week intensive experiential training for endocrinologists includes a 1-week hospitalization experience at Ruijin Hospital, involving health examinations, results interpretation, and integrated training courses for T2DM management.~During the patient intervention period, endocrinologists will each manage approximately 10 T2DM patients, conduct regular follow-ups, and participate in regular training sessions, including experience-sharing meetings.
Study NCT05715307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular training for endocrinologists in T2DM management
Description: Regular training and communication are implemented by Ruijin Hospital under the guidance of T2DM management.~During the patient intervention period, endocrinologists will each manage approximately 10 T2DM patients, conduct regular follow-ups, and receive regular routine training.
Study NCT05794971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib and DIBIRI
Description: Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)~Drug: Irinotecan it will be mixed in eluting-beads and injected in the tumor.~Procedure: TACE Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to decrease the tumor's blood supply.~Device: drug eluting-bead The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.
Study NCT05794971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)
Study NCT06501352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Additive to Local anesthetic mixture
Study NCT05148208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Creatine supplementation to dialysate
Description: Creatine supplementation to dialysate
Study NCT05148208 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Creatine supplementation to dialysate
Description: Creatine supplementation to dialysate
Study NCT05397873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Description: The training of oculomotor functions is done on the biofeedback module of a microperimeter MAIA.
Study NCT06182280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP4T
Description: PrEP4T is an individualized TMSM-specific intervention adapted from The Fenway Model. PrEP4T consists of online one-on-one sessions between a peer and a participant using a strengths-based case management manualized curriculum. Peer navigators (PNs) share transmasculine community membership with participants and are trained to provide linkages. They use an individualized approach to navigate barriers, apply an assets-based frame to promote resiliencies, and pragmatically leverage these to improve biomedical HIV prevention outcomes. PNs utilize techniques from established behavior change models (e.g., Motivational Interviewing; Transtheoretical Model) in PrEP decision-making.
Study NCT06182280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LS4TM
Description: LS4TM is a theory-based peer-delivered small group-based behavioral intervention to reduce HIV risk and address mental health-related effects of stigma for TMSM. Groups will be led by trained peer navigator staff and comprise no more than 10 participants per cohort.
Study NCT06501352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Additive to Local anesthetic mixture
Study NCT04842422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75% Cream
Description: Imiquimod 3.75% Cream
Study NCT06501352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control
Study NCT06173141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low- to moderate-continuous intensity cycling exercises:
Description: aerobic exercise during dialysis using Pedal machine at low- to moderate continuous intensity rating from 11 to 13 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities
Study NCT06173141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moderate- to high-interval intensity cycling exercises
Description: aerobic exercise during dialysis using Pedal machine at moderate-to-high interval intensity rating from 12 to 15 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities